scPharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Burlington MA United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2014
NCT02350725
First Marketed Drug
2022
furosemide (lasix)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

SCPHARMACEUTICALS | scPharmaceuticals, Inc.